Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,103 active trials29 approved drugs653 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03613727 | Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients | completed | Phase 2 | 61 | Virginia Commonwealth UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT03671564 | Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) | completed | Phase 1 | 14 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT04055844 | Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | completed | Phase 2 | 14 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02782468 | A Study of Pevonedistat in Adult East Asian Participants | completed | Phase 1 | 23 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Nov 3, 2023 | clinicaltrials |
| NCT02989844 | Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT | completed | Phase 2 | 20 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT03728699 | Microbiota Changes in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy | completed | — | 54 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT01404741 | 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS) | completed | Phase 2 | 191 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT03262974 | Effect of Pharmacogenetics on Imatinib Plasma Level and Response | completed | — | 60 | Assiut UniversityOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT02117297 | SCT Plus Immune Therapy in Average Risk AML/MDS | completed | Phase 2 | 26 | New York Medical CollegeOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT02221310 | Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS | completed | Phase 2 | 25 | New York Medical CollegeOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT00571662 | Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant | completed | Phase 2 | 76 | University of NebraskaOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT00611351 | Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer | completed | Phase 2 | 5 | University of NebraskaOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT02916979 | Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG(FluBuATG) | completed | Phase 1 | 20 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT03701295 | Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement | completed | Phase 1 / Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05048498 | Pharmacokinetics, Tolerability and Safety of NEX-18a | completed | Phase 1 | 2 | Nanexa ABINDUSTRY | 1 | Oct 17, 2023 | clinicaltrials |
| NCT04075747 | A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia(V-FAST) | completed | Phase 1 | 57 | Jazz PharmaceuticalsINDUSTRY | 1 | Oct 16, 2023 | clinicaltrials |
| NCT03096782 | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | completed | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT01712308 | Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia | completed | Phase 2 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT02649764 | Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT02546375 | A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands | completed | — | 87 | PfizerINDUSTRY | 1 | Oct 3, 2023 | clinicaltrials |
| NCT01056523 | Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 29 | Jewish General HospitalOTHER | 1 | Oct 2, 2023 | clinicaltrials |
| NCT02073838 | Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML | completed | Phase 2 | 23 | Sarit AssoulineOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT02767388 | Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery(Chemobrain) | completed | — | 45 | University of NebraskaOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT02771197 | Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant | completed | Phase 2 | 20 | Northside Hospital, Inc.OTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04048564 | Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®) | completed | — | 120 | Incyte BioSciences FranceINDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT01428635 | Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy | completed | Phase 2 / Phase 3 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT03625388 | Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia | completed | Phase 2 | 56 | Hikma Pharmaceuticals LLCINDUSTRY | 4 | Sep 22, 2023 | clinicaltrials |
| NCT00003838 | Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow | completed | Phase 2 | 202 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 21, 2023 | clinicaltrials |
| NCT02122081 | Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | completed | Phase 1 | 33 | Sumithira VasuOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT02661035 | Allo HSCT Using RIC for Hematological Diseases | completed | Phase 2 | 156 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT00106600 | Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML) | completed | Phase 1 / Phase 2 | 12 | CTI BioPharmaINDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT04774744 | Effect of Digital Health Coaching Program on Self-efficacy and Patient Reported Outcomes of Patients With Newly Diagnosed Acute Myeloid Leukemia or Chronic Lymphocytic Leukemia | completed | N/A | 157 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT06042660 | Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis | completed | — | 527 | Polish Adult Leukemia GroupOTHER | 0 | Sep 18, 2023 | clinicaltrials |
| NCT01696461 | A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor | completed | Phase 2 | 127 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Sep 14, 2023 | clinicaltrials |
| NCT01951885 | Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention | completed | Phase 3 | 101 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT02642965 | Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 38 | Children's Oncology GroupNETWORK | 2 | Sep 8, 2023 | clinicaltrials |
| NCT02873338 | Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 75 | Jazz PharmaceuticalsINDUSTRY | 1 | Sep 7, 2023 | clinicaltrials |
| NCT03390296 | OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 5, 2023 | clinicaltrials |
| NCT03537560 | Detection of IDH2 Mutations and Monitoring Molecular Residual Disease in Patients With AML | completed | — | 334 | Chang Gung Memorial HospitalOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT04402541 | Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 55 | Cleave Therapeutics, Inc.INDUSTRY | 2 | Aug 31, 2023 | clinicaltrials |
| NCT03531918 | Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm | completed | Phase 1 / Phase 2 | 66 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT04443751 | A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | completed | Phase 1 | 31 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 24, 2023 | clinicaltrials |
| NCT03512197 | A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) | completed | Phase 3 | 511 | Novartis PharmaceuticalsINDUSTRY | 20 | Aug 21, 2023 | clinicaltrials |
| NCT04712942 | Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat | completed | Phase 2 | 14 | University of LeipzigOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05734053 | Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line(NOFRETETE) | completed | — | 222 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT03030612 | A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 38 | OncoVerity, Inc.INDUSTRY | 2 | Aug 9, 2023 | clinicaltrials |
| NCT02936089 | Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+ | completed | N/A | 207 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Aug 8, 2023 | clinicaltrials |
| NCT00516828 | Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 21 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Nov 7, 2023source: clinicaltrials